Circio Holding ASA, a biotechnology company advancing circular RNA technologies for next-generation nucleic acid medicines, and Entos Pharmaceuticals U.K. Ltd. (Entos), a clinical-stage company specializing in genetic medicine, today announced the initiation of a research collaboration. This partnership will focus on the joint development and in vivo delivery assessment of Circio’s optimized circular RNA expression vectors (circVec) using Entos’ proprietary Fusogenix™ PLV™ nucleic acid delivery platform.

As part of the agreement, Entos will develop and validate PLV-formulations of Circio's circVec DNA vectors and conduct in vivo technical testing. Preliminary data from the collaboration is anticipated within three to six months. If successful, these findings will lay the groundwork for an extended partnership focused on advancing circVec-PLV therapeutic candidates with potential applications in genetic medicine, chronic disease treatment, and vaccine development.

Financial terms of the collaboration were not disclosed.

Entos has demonstrated efficient and safe delivery of synthetic non-viral DNA vectors in preclinical models and clinical trials, said Dr. Thomas Hansen, CTO of Circio. Their unique PLV technology facilitates direct fusion with cell membranes, bypassing the endosomal pathway—an approach that improves delivery efficiency while minimizing toxicity. This collaboration represents a strategic step in exploring the powerful synergy between Circio’s circular RNA platform and Entos’ delivery technology. Together, we aim to establish a shared foundation for developing therapeutic solutions targeting areas of significant unmet medical need.

Entos is currently collaborating with several global genetic medicine leaders to broaden the application of our Fusogenix PLV delivery system, said Jason Ding, Chief Business Officer at Entos Pharmaceuticals. We’re excited to partner with Circio, whose innovative approach to circular RNA vector expression is well-aligned with our mission. Through this collaboration, we hope to enhance the delivery efficiency of circVec DNA vectors and reduce toxicity compared to traditional lipid nanoparticle (LNP) systems—potentially unlocking impactful new treatments in genetic medicine, chronic disease, and vaccines.

Source: https://entospharma.com/news-%26-media/f/entos-circio-collaborate-on-in-vivo-plv-circvec-delivery